Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
PCSK9 inhibitors have had trouble gaining tracking in the marketplace. Since about 2015, a number of companies have received approval for these drugs but struggled with sales.
Between the numerous COVID-19 vaccines and several new antiviral drugs, it would appear that the tools to end the COVID-19 pandemic are within reach. Here’s a look at some of the top stories.
Recludix launches with a mission to develop Three SH2 domain inhibitor programs targeting STAT3, STAT6, and an undisclosed non-STAT target for cancer and inflammatory disease targets.
Thanks partly to Biogen’s pricey new Alzheimer’s drug, Medicare enrollees will be burdened with higher monthly premiums for their Part B coverage.
The research showed that 61% of patients with PV experienced a complete hematological response after 7.5 years of treatment with BESREMi. Here’s more about it.
If bentracimab continues to yield the desired results through the rest of the Phase III study, PhaseBio will be on track to file a Biologics License Application in mid-2022.
The investigational drug directs a patient’s own IL-2 toward immune activation while simultaneously preventing IL-2’s immune suppression activities.
President Joe Biden has nominated former U.S. Food and Drug Administration Commissioner Robert Califf to reprise his role at the agency’s helm.
It’s been a week of gained and lost opportunities after two large biopharmaceutical firms announced changes to their staff rosters.
It was another busy week for clinical trial news. Here’s a look.
The total revenue for the quarter was $9.74 billion, a leap of 47%. The COVID-19 vaccine, Vaxzevria, only contributed 1% to the company’s profit.
Boston-based Biogen shared data from two Phase III studies at the Clinical Trials on Alzheimer’s Disease conference that showed the latest efficacy data of Aduhelm (aducanumab).